{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:15:40Z","timestamp":1792512940829,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd011144","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T00:00:00Z","timestamp":1511222400000}}],"reference-count":120,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011144.pub2","type":"journal-article","created":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T20:48:18Z","timestamp":1511210898000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Methylphenidate for children and adolescents with autism spectrum disorder"],"prefix":"10.1002","volume":"2017","author":[{"given":"Nancy","family":"Sturman","sequence":"first","affiliation":[{"name":"The University of Queensland; Primary Care Clinical Unit, Faculty of Medicine; Herston Brisbane Queensland Australia 4029"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Deckx","sequence":"additional","affiliation":[{"name":"The University of Queensland; Primary Care Clinical Unit, Faculty of Medicine; Herston Brisbane Queensland Australia 4029"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke L","family":"van Driel","sequence":"additional","affiliation":[{"name":"The University of Queensland; Primary Care Clinical Unit, Faculty of Medicine; Herston Brisbane Queensland Australia 4029"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,21]]},"reference":[{"key":"10.1002\/14651858.CD011144.pub2-BIB0002|cit1","unstructured":"Handen BL Cochrane Review: Methylphenidate for core and ADHD-like symptoms in children aged 6 to 18 years with autism spectrum disorders (ASDs)\u200b [personal communication] Email to: N Sturman"},{"issue":"3","key":"10.1002\/14651858.CD011144.pub2-BIB0001|cit2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1023\/A:1005548619694","article-title":"Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder","volume":"30","author":"Handen","year":"2000","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0004|cit3","unstructured":"Pearson DA Cochrane Review: Methylphenidate for core and ADHD-like symptoms in children aged 6 to 18 years with autism spectrum disorders (ASDs)\u200b [personal communication] Email to: N Sturman"},{"issue":"5","key":"10.1002\/14651858.CD011144.pub2-BIB0003|cit4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/cap.2012.0096","article-title":"Effects of extended release methylphenidate treatment on ratings of attention-deficit\/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms","volume":"23","author":"Pearson","year":"2013","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011144.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF02179289","article-title":"Use of methylphenidate in the treatment of children with autistic disorder","volume":"25","author":"Quintana","year":"1995","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"3","key":"10.1002\/14651858.CD011144.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s10803-008-0636-9","article-title":"Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity","volume":"39","author":"Jahromi","year":"2009","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0010|cit7","unstructured":"Posey DJ Cochrane Review: Methylphenidate for core and ADHD-like symptoms in children aged 6 to 18 years with autism spectrum disorders (ASDs)\u200b [personal communication] Email to: N Sturman"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011144.pub2-BIB0007|cit8","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.1038\/sj.npp.1301266","article-title":"Methylphenidate in pervasive developmental disorders: an analysis of secondary measures","volume":"31","author":"Posey","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD011144.pub2-BIB0008|cit9","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.biopsych.2006.09.028","article-title":"Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures","volume":"61","author":"Posey","year":"2007","journal-title":"Biological Psychiatry"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD011144.pub2-BIB0009|cit10","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1038\/sj.npp.1300647","article-title":"A randomized, double-blind, placebo-controlled, crossover trial of methylphenidate in children with hyperactivity associated with pervasive developmental disorders","volume":"29","author":"Posey","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD011144.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/archpsyc.62.11.1266","article-title":"Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity","volume":"62","author":"Research Units on Pediatric Psychopharmacology Autism Network","year":"2005","journal-title":"Archives of General Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011144.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"S233","DOI":"10.1007\/s00787-015-0714-4","article-title":"Altered response with methylphenidate to adhd-like symptoms in pervasive developmental disorder: does CES-1 enzyme gene polymorphism have a role?","volume":"24","author":"Ercan","year":"2015","journal-title":"European Child & Adolescent Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011144.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF02284761","article-title":"Prediction of clinical response in children taking methylphenidate","volume":"21","author":"Aman","year":"1991","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"5","key":"10.1002\/14651858.CD011144.pub2-BIB0014|cit14","first-page":"521","article-title":"Fenfluramine and methylphenidate in children with mental retardation and borderline IQ: clinical effects","volume":"101","author":"Aman","year":"1997","journal-title":"American Journal of Mental Retardation"},{"issue":"12","key":"10.1002\/14651858.CD011144.pub2-BIB0015|cit15","first-page":"1399","article-title":"Practice guidelines: AAP releases guidelines on management of autism spectrum disorders","volume":"78","author":"Armstrong","year":"2008","journal-title":"American Family Physician"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0016|cit16","doi-asserted-by":"crossref","unstructured":"Barnard-Brak L Davis TN Schmidt M Richman DM Effects associated with on- and off-label stimulant treatment of core autism and ADHD symptoms exhibited by children with autism spectrum disorder Developmental Neurorehabilitation 2016 46 53 10.3109\/17518423.2014.904949","DOI":"10.3109\/17518423.2014.904949"},{"issue":"2","key":"10.1002\/14651858.CD011144.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/00004583-198803000-00020","article-title":"Methylphenidate treatment of hyperactive autistic children","volume":"27","author":"Birmaher","year":"1988","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011144.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1001\/archgenpsychiatry.2011.38","article-title":"Epidemiology of autism spectrum disorders in adults in the community in England","volume":"68","author":"Brugha","year":"2011","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011144.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.5336\/medsci.2015-43336","article-title":"Atomoxetine versus OROS methylphenidate in attention deficit hyperactivity disorder: a six-month follow up study for efficacy and adverse effects","volume":"35","author":"\u00c7et\u00edn","year":"2015","journal-title":"Turkiye Klinikleri Journal of Medical Sciences"},{"issue":"7","key":"10.1002\/14651858.CD011144.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"A552","DOI":"10.1016\/j.jval.2013.08.1429","article-title":"PMH60 - Psychoactive drug use, polypharmacy and co-morbidities in newly diagnosed patients with pervasive development disorder in the province of Quebec","volume":"16","author":"Croteau","year":"2013","journal-title":"Value in Health"},{"issue":"2","key":"10.1002\/14651858.CD011144.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/1044546041649011","article-title":"Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study","volume":"14","author":"Martino","year":"2004","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD011144.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/npp.2010.243","article-title":"Effects of stimulant medication, incentives, and event rate on reaction time variability in children with ADHD","volume":"36","author":"Epstein","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD011144.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1089\/104454601750284081","article-title":"Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a reanalysis using drug-placebo and drug-drug response curve methodology","volume":"11","author":"Faraone","year":"2001","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD011144.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1469-8749.2008.02039.x","article-title":"Effects of methylphenidate on quality of life in children with both developmental coordination disorder and ADHD","volume":"50","author":"Flapper","year":"2008","journal-title":"Developmental Medicine and Child Neurology"},{"issue":"4","key":"10.1002\/14651858.CD011144.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1089\/cap.2008.0137","article-title":"Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit\/hyperactivity disorder symptoms in preschoolers with developmental disorders","volume":"19","author":"Ghuman","year":"2009","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0026|cit26","doi-asserted-by":"crossref","unstructured":"Gurbuz F Gurbuz BB Celik GG Yildirim V Ucakturk SA Seydaoglu G Effects of methylphenidate on appetite and growth in children diagnosed with attention deficit and hyperactivity disorder Journal of Pediatric Endocrinology & Metabolism 2016 85 92 10.1515\/jpem-2015-0171","DOI":"10.1515\/jpem-2015-0171"},{"issue":"12","key":"10.1002\/14651858.CD011144.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1469-8749.1994.tb11811.x","article-title":"Methylphenidate and ADHD: influence of age, IQ and neurodevelopmental status","volume":"36","author":"Mayes","year":"1994","journal-title":"Developmental Medicine and Child Neurology"},{"issue":"1","key":"10.1002\/14651858.CD011144.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1744-6171.2007.00080.x","article-title":"Treatment of hyperactivity in children with pervasive developmental disorders","volume":"20","author":"Scahill","year":"2007","journal-title":"Journal of Child and Adolescent Psychiatric Nursing"},{"issue":"2","key":"10.1002\/14651858.CD011144.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/ebmh.9.2.45","article-title":"Methylphenidate hydrochloride reduces hyperactivity in children with pervasive development disorders","volume":"9","author":"Shea","year":"2006","journal-title":"Evidence-Based Mental Health"},{"issue":"5","key":"10.1002\/14651858.CD011144.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1469-7610.2012.02569.x","article-title":"Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability","volume":"54","author":"Simonoff","year":"2013","journal-title":"Journal of Child Psychology and Psychiatry, and Allied Disciplines"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0031|cit31","doi-asserted-by":"crossref","unstructured":"Sinzig J Vinzelberg I Evers D Lehmkuhl G Executive function and attention profiles in preschool and elementary school children with autism spectrum disorders or ADHD International Journal of Developmental Disabilities 2014 144 54 10.1179\/2047387714y.0000000040","DOI":"10.1179\/2047387714Y.0000000040"},{"issue":"1","key":"10.1002\/14651858.CD011144.pub2-BIB0032|cit32","first-page":"e50","article-title":"A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder","volume":"13","author":"Steele","year":"2006","journal-title":"Canadian Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0033|cit33","doi-asserted-by":"crossref","unstructured":"Von Morgenstern SB Becker I Sinzig J Improvement of facial affect recognition in children and adolescents with attention-deficit\/hyperactivity disorder under methylphenidate Acta Neuropsychiatrica 2014 202 8 10.1017\/neu.2013.55","DOI":"10.1017\/neu.2013.55"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0034|cit34","unstructured":"Australian Advisory Board on Autism Spectrum Disorders The prevalence of autism in Australia: can it be established from existing data? www.autismadvisoryboard.org.au\/uploads\/Autism%20Prevalence%20Study%20FINAL%20Feb%2007.pdf"},{"issue":"5","key":"10.1002\/14651858.CD011144.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1542\/peds.107.5.1221","article-title":"American Academy of Pediatrics: the pediatrician's role in the diagnosis and management of autistic spectrum disorder in children","volume":"107","author":"Committee on Children with Disabilities","year":"2001","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0036|cit36","volume-title":"Parenting Stress Index: Manual, Administration Booklet, [and] Research Update","author":"Abidin","year":"1983"},{"issue":"4","key":"10.1002\/14651858.CD011144.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/BF01538326","article-title":"Stimulant drug effects in developmental disorders and hyperactivity--toward a resolution of disparate findings","volume":"12","author":"Aman","year":"1982","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"12","key":"10.1002\/14651858.CD011144.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1097\/00004583-199512000-00018","article-title":"Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use","volume":"34","author":"Aman","year":"1995","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011144.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/104454603321666171","article-title":"Methylphenidate treatment in children with borderline IQ and mental retardation: analysis of three aggregated studies","volume":"13","author":"Aman","year":"2003","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011144.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.psc.2008.10.004","article-title":"New developments in autism","volume":"32","author":"Bertoglio","year":"2009","journal-title":"The Psychiatric Clinics of North America"},{"issue":"5","key":"10.1002\/14651858.CD011144.pub2-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1001\/archgenpsychiatry.2011.38","article-title":"Epidemiology of autism spectrum disorders in adults in the community in England","volume":"68","author":"Brugha","year":"2011","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0042|cit42","first-page":"226","article-title":"Attention and autism: behavioral and electrophysiological evidence","volume-title":"Handbook of Autism and Pervasive Developmental Disorder","author":"Burack","year":"1997"},{"issue":"1","key":"10.1002\/14651858.CD011144.pub2-BIB0043|cit43","first-page":"17-27","article-title":"From clinical application to cognitive enhancement: the example of methylphenidate","volume":"14","author":"Busard\u00f2","year":"2016","journal-title":"Current Neuropharmacology"},{"issue":"4","key":"10.1002\/14651858.CD011144.pub2-BIB0044|cit44","first-page":"399","article-title":"Pharmacotherapy in early infantile autism","volume":"10","author":"Campbell","year":"1975","journal-title":"Biological Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD011144.pub2-BIB0045|cit45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007849.pub2","article-title":"Acupuncture for autism spectrum disorders (ASD)","author":"Cheuk","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD011144.pub2-BIB0046|cit46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009043.pub2","article-title":"Aripiprazole for autism spectrum disorders (ASD)","author":"Ching","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.brainres.2010.12.085","article-title":"Methylphenidate normalizes emotional processing in adult patients with attention-deficit\/hyperactivity disorder: preliminary findings","volume":"1381","author":"Conzelmann","year":"2011","journal-title":"Brain Research"},{"issue":"4","key":"10.1002\/14651858.CD011144.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1586\/ern.12.23","article-title":"Psychostimulants for ADHD-like symptoms in individuals with autism spectrum disorders","volume":"12","author":"Cortese","year":"2012","journal-title":"Expert Review of Neurotherapeutics"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0049|cit49","unstructured":"Deeks JJ Higgins JPT Altman DG editor(s) Chapter 9: Analysing data and undertaking metaanalyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD011144.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s12402-016-0201-x","article-title":"Is emotion recognition the only problem in ADHD? Effects of pharmacotherapy on face and emotion recognition in children with ADHD","volume":"8","author":"Demirci","year":"2016","journal-title":"Attention Deficit and Hyperactivity Disorders"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0051|cit51","volume-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-III","author":"American Psychiatric Association","year":"1980"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0052|cit52","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5","author":"American Psychiatric Association","year":"2013"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0053|cit53","volume-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-IV","author":"American Psychiatric Association","year":"1994"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0054|cit54","volume-title":"Diagnostic and Stastical Manual of Mental Disorders: DSM-IV-TR. 4th edition, Text Revision","author":"American Psychiatric Association","year":"2000"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0055|cit55","doi-asserted-by":"crossref","DOI":"10.1002\/9780470693926","volume-title":"Systematic Reviews in Health Care: Meta-Analysis in Context","author":"Egger","year":"2001"},{"issue":"2","key":"10.1002\/14651858.CD011144.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/108705470100500204","article-title":"Validation of the ADHD Rating Scale as a clinician administered and scored instrument","volume":"5","author":"Faries","year":"2001","journal-title":"Journal of Attention Disorders"},{"issue":"6","key":"10.1002\/14651858.CD011144.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1023\/A:1021943802493","article-title":"The screening and diagnosis of autistic spectrum disorders","volume":"29","author":"Filipek","year":"1999","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"4","key":"10.1002\/14651858.CD011144.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1212\/WNL.55.4.468","article-title":"Practice parameter: screening and diagnosis of autism: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society","volume":"55","author":"Filipek","year":"2000","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD011144.pub2-BIB0059|cit59","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008785.pub2","article-title":"Interventions based on the Theory of Mind cognitive model for autism spectrum disorder (ASD)","author":"Fletcher-Watson","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD011144.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/108705470100400402","article-title":"Should the diagnosis of attention-deficit\/ hyperactivity disorder be considered in children with pervasive developmental disorder?","volume":"4","author":"Frazier","year":"2001","journal-title":"Journal of Attention Disorders"},{"issue":"6","key":"10.1002\/14651858.CD011144.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1089\/cap.2011.0057","article-title":"Prevalence and correlates of psychotropic medication use in adolescents with an autism spectrum disorder with and without caregiver-reported attention-deficit\/hyperactivity disorder","volume":"21","author":"Frazier","year":"2011","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD011144.pub2-BIB0062|cit62","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004381.pub3","article-title":"Music therapy for people with autism spectrum disorder","author":"Geretsegger","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0063|cit63","doi-asserted-by":"crossref","unstructured":"GRADE Working Group Grading quality of evidence and strength of recommendations BMJ 2004 1490 10.1136\/bmj.328.7454.1490","DOI":"10.1136\/bmj.328.7454.1490"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0064|cit64","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"issue":"9","key":"10.1002\/14651858.CD011144.pub2-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1002\/aur.1596","article-title":"Improvement by methylphenidate and atomoxetine of social interaction deficits and recognition memory impairment in a mouse model of valproic acid-induced autism","volume":"9","author":"Hara","year":"2016","journal-title":"Autism Research"},{"issue":"4","key":"10.1002\/14651858.CD011144.pub2-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s10802-007-9110-y","article-title":"Modeling rater disagreement for ADHD: are parents or teachers biased?","volume":"35","author":"Hartman","year":"2007","journal-title":"Journal of Abnormal Child Psychology"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0067|cit67","unstructured":"Higgins JPT Deeks JJ Altman DG editor(s) Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0068|cit68","unstructured":"Higgins JPT Deeks JJ editor(s) Chapter 7: Selecting Studies and collecting data. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0069|cit69","unstructured":"Higgins JPT Deeks JJ Altman DG editor(s) Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0070|cit70","unstructured":"Higgins JPT Altman DG Sterne JAC editor(s) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"3","key":"10.1002\/14651858.CD011144.pub2-BIB0071|cit71","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008372.pub2","article-title":"Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents","author":"Hurwitz","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0072|cit72","unstructured":"Hyman SL AAP news: new DSM-5 includes changes to autism criteria aapnews.aappublications.org\/content\/early\/2013\/06\/04\/aapnews.20130604-1"},{"issue":"11","key":"10.1002\/14651858.CD011144.pub2-BIB0073|cit73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007992.pub2","article-title":"Omega-3 fatty acids supplementation for autism spectrum disorders (ASD)","author":"James","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD011144.pub2-BIB0074|cit74","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010766.pub2","article-title":"Chelation for autism spectrum disorder (ASD)","author":"James","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0075|cit75","doi-asserted-by":"crossref","unstructured":"Jensen JS Bielefeldt A\u00d8 Hr\u00f3bjartsson A Active placebo control groups of pharmacological interventions were rarely used but merited serious consideration: a methodological overview Journal of Clinical Epidemiology 2017 July [Epub ahead of print] 10.1016\/j.jclinepi.2017.03.001","DOI":"10.1016\/j.jclinepi.2017.03.001"},{"issue":"1","key":"10.1002\/14651858.CD011144.pub2-BIB0076|cit76","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005040.pub2","article-title":"Risperidone for autism spectrum disorder","author":"Jesner","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0077|cit77","first-page":"217","article-title":"Autistic disturbances of affective contact","volume":"2","author":"Kanner","year":"1943","journal-title":"Nervous Child"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/978-1-907673-42-9_2","article-title":"Rating scales for the assessment of ADHD","volume-title":"Guide to Assessment Scales in Attention-deficit\/Hyperactivity Disorder","author":"Kollins","year":"2010"},{"issue":"8","key":"10.1002\/14651858.CD011144.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s10803-006-0147-5","article-title":"Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification","volume":"36","author":"Lecavalier","year":"2006","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"7","key":"10.1002\/14651858.CD011144.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLOS Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011144.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1023\/A:1005592401947","article-title":"The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism","volume":"30","author":"Lord","year":"2000","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/9781118911389.hautc25","article-title":"Diagnostic instruments in autistic spectrum disorders","volume-title":"Handbook of Autism and Pervasive Developmental Disorders","volume":"2: assessment,","author":"Lord","year":"2014"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0083|cit83","unstructured":"Mayo Clinic Methylphenidate (oral route) www.mayoclinic.com\/health\/drug-information\/DR601847\/DSECTION=proper-use"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0084|cit84","unstructured":"New Zealand Medicines and Medical Devices Safety Authority Methylphenidate - updated guidance when treating children www.medsafe.govt.nz\/profs\/PUArticles\/Methylphenidate.htm"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0085|cit85","unstructured":"National Institute for Health and Care Excellence Autism in under 19s: support and management www.nice.org.uk\/Guidance\/CG170"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0086|cit86","unstructured":"Eunice Kennedy Shriver National Institute of Child Health and Human Development Autism spectrum disorder (ASD): overview www.nichd.nih.gov\/health\/topics\/autism\/Pages\/default.aspx"},{"issue":"5","key":"10.1002\/14651858.CD011144.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1023\/A:1005511809545","article-title":"Commentary: considerations on the pharmacotherapy of attention deficits and hyperactivity in children with autism and other pervasive developmental disorders","volume":"30","author":"Nicolson","year":"2000","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0088|cit88","unstructured":"Novartis Pharmaceuticals Canada Inc Product Monograph Ritalin, Ritalin SR www.novartis.ca\/en\/our-products\/pharmaceuticals#ui-id-1=14\u200b"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/978-3-319-16522-6_10","article-title":"Social cognition","volume-title":"Handbook of Experimental Pharmacology: Cognitive Enhancement","volume":"228","author":"Patin","year":"2015"},{"issue":"4","key":"10.1002\/14651858.CD011144.pub2-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"386-92","DOI":"10.1097\/YCO.0b013e3281568d7a","article-title":"Epidemiology of attention-deficit\/hyperactivity disorder across the lifespan","volume":"20","author":"Polanczyk","year":"2007","journal-title":"Current Opinion in Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD011144.pub2-BIB0091|cit91","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009260.pub2","article-title":"Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD)","author":"Reichow","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD011144.pub2-BIB0092|cit92","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008511.pub2","article-title":"Social skills groups for people aged 6 to 21 with autism spectrum disorders (ASD)","author":"Reichow","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0093|cit93","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"3","key":"10.1002\/14651858.CD011144.pub2-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jaac.2012.12.007","article-title":"The Preschool Attention-Deficit\/Hyperactivity Disorder Treatment Study (PATS) 6-year follow-up","volume":"52","author":"Riddle","year":"2013","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0095|cit95","volume-title":"Australian Medicines Handbook","author":"Rossi","year":"2010"},{"issue":"5","key":"10.1002\/14651858.CD011144.pub2-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/j.1365-2214.2006.00631.x","article-title":"Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study","volume":"32","author":"Santosh","year":"2006","journal-title":"Child: Care, Health and Development"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD011144.pub2-BIB0097|cit97","first-page":"19","article-title":"Diagnosis and evaluation of pervasive developmental disorders","volume":"66","author":"Scahill","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD011144.pub2-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1097\/01.chi.0000220854.79144.e7","article-title":"Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders","volume":"45","author":"Scahill","year":"2006","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD011144.pub2-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.euroneuro.2010.05.001","article-title":"Childhood methylphenidate treatment of ADHD and response to affective stimuli","volume":"21","author":"Schlochtermeier","year":"2011","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0100|cit100","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"8","key":"10.1002\/14651858.CD011144.pub2-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1007\/s10803-011-1399-2","article-title":"Psychotropic medications in children with autism spectrum disorders: a systematic review and synthesis for evidence-based practice","volume":"42","author":"Siegel","year":"2012","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0102|cit102","unstructured":"Scottish Intercollegiate Guidelines Network Assessment, diagnosis and clinical interventions for children and young people with autism spectrum disorders: a national clinical guideline www.sign.ac.uk\/pdf\/sign98.pdf"},{"issue":"12","key":"10.1002\/14651858.CD011144.pub2-BIB0103|cit103","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003681.pub3","article-title":"Auditory integration training and other sound therapies for autism spectrum disorders (ASD)","author":"Sinha","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0104|cit104","volume-title":"Essentials of Conners Behaviour Assessments","author":"Sparrow","year":"2010"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0105|cit105","unstructured":"Sterne JAC Egger M Moher D Boutron I editor(s) Chapter 10: Addressing reporting biases. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"11","key":"10.1002\/14651858.CD011144.pub2-BIB0106|cit106","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009885.pub2","article-title":"Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)","author":"Storeb\u00f8","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD011144.pub2-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40489-014-0016-7","article-title":"The effects of DSM5 autism diagnostic criteria on number of individuals diagnosed with autism spectrum disorders: a systematic review","volume":"1","author":"Sturmey","year":"2014","journal-title":"Review Journal of Autism and Developmental Disorders"},{"issue":"8","key":"10.1002\/14651858.CD011144.pub2-BIB0108|cit108","first-page":"1355","article-title":"Attention-deficit\/hyperactivity disorder: management","volume":"64","author":"Szymanski","year":"2001","journal-title":"American Family Physician"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0109|cit109","volume-title":"Management Guidelines: Developmental Disability","author":"Therapeutic Guidelines","year":"2012"},{"issue":"4","key":"10.1002\/14651858.CD011144.pub2-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.biopsych.2007.01.001","article-title":"Developmental Disabilities modification of Children's Global Assessment Scale (DD-CGAS)","volume":"61","author":"Wagner","year":"2007","journal-title":"Biological Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011144.pub2-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/j.1651-2227.2008.01214.x","article-title":"The Conners' 10-item scale: findings in a total population of Swedish 10-11-year-old children","volume":"98","author":"Westerlund","year":"2009","journal-title":"Acta Paediatrica"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0112|cit112","volume-title":"The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines","author":"World Health Organization","year":"2007"},{"issue":"3 Suppl 2","key":"10.1002\/14651858.CD011144.pub2-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1097\/JCP.0b013e318173312f","article-title":"Effects of methylphenidate on the catecholaminergic system in attention-deficit\/hyperactivity disorder","volume":"28","author":"Wilens","year":"2008","journal-title":"Journal Of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011144.pub2-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/adc.2004.062083","article-title":"Systematic review of prevalence studies of autism spectrum disorders","volume":"91","author":"Williams","year":"2006","journal-title":"Archives of Disease in Childhood"},{"issue":"10","key":"10.1002\/14651858.CD011144.pub2-BIB0115|cit115","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.biopsych.2007.11.022","article-title":"Misinterpreting emotional expressions in attention-deficit\/hyperactivity disorder: evidence for a neural marker and stimulant effects","volume":"63","author":"Williams","year":"2008","journal-title":"Biological Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011144.pub2-BIB0116|cit116","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003495.pub3","article-title":"Intravenous secretin for autism spectrum disorders (ASD)","author":"Williams","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD011144.pub2-BIB0117|cit117","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004677.pub3","article-title":"Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)","author":"Williams","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9093","key":"10.1002\/14651858.CD011144.pub2-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0140-6736(97)09218-0","article-title":"The autistic spectrum","volume":"350","author":"Wing","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011144.pub2-BIB0119|cit119","doi-asserted-by":"crossref","unstructured":"Zhang S Faries DE Vowles M Michelson D ADHD Rating Scale IV: psychometric properties from a multinational study as a clinician-administered instrument International Journal of Methods in Psychiatric Research 2005 186 201","DOI":"10.1002\/mpr.7"},{"issue":"8","key":"10.1002\/14651858.CD011144.pub2-BIB0120|cit120","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011144","article-title":"Methylphenidate for core and ADHD-like symptoms in children aged 6 to 18 years with autism spectrum disorders (ASDs)","author":"Redman","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD011144.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T05:19:06Z","timestamp":1685596746000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011144.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Developmental, Psychosocial and Learning Problems Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,11,21]]},"references-count":120,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011144.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,21]]}}}